BioSpace News Archive

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, announced the appointment of Matthew Roden, Ph.D., to its Board of Directors.

NovaBay Pharmaceuticals, Inc. announces the consumer launch of Clinical Reset, an FDA-cleared skincare product proven to help clean and reduce the buildup of bacteria on facial skin.

Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, announced that Craig Parker, president and chief executive officer of Surrozen, will be presenting at the Stifel 2020 Virtual Healthcare Conference.

PDUFA Target Action Date of June 5, 2021 for Ryplazim ® (plasminogen) BLA Submission Ryplazim ® (plasminogen) Abstracts Selected for Presentation at American Society of Hematology (ASH) in early December Changes to Board of Directors OXER1 Antagonist Preclinical R&D Program Acquired New Appointments to Board of Directors

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announced its financial results for the third quarter ending September 30, 2020 and provided a corporate update. The filing is available on SEDAR. Financial and corporate highlights include: Completion of financings for gross proceeds of $19.5 million USD through two registered direct offerings. As of September 30, 2020, cash & non-

- Sumitovant Biopharma to acquire all outstanding shares of Urovant it does not already own - Transaction increases Urovant’s ability to provide patient therapies and achieve commercial success as it prepares to launch its first potential therapy, vibegron, for the treatment of patients with overactive bladder (OAB) - Agreement unanimously recommended by Special Committee of Urovant Independent Directors

Urovant Sciences Shareholders to Receive $16.25 per share in cash Urovant Special Independent Committee of the Board Unanimously Recommends that all Shareholders Vote in Favor of the Transaction Agreement Represents Confidence in Urovant’s Future Success Transaction expected to be completed in Q1 2021, subject to approval by a majority of minority shareholders IRVINE, Calif. & BASEL, Switzerland--( BUSINESS WIRE )-- Urova

Presented positive clinical proof-of-concept data from ongoing ALRN-6924 Phase 1b trial in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan in late-breaking presentation at 2020 EORTC-NCI-AACR Annual Symposium Phase 1b randomized, controlled trial in patients with p53-mutated advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy projected to start in the second quarter of 2021

Adagio Medical, Inc., a leading innovator for the treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), and developer of the intelligent Continuous Lesion Ablation System (iCLAS™), today announced that it has closed a $42.5 million Series E equity financing.

SOFIE, an established Radiopharmaceutical Contract Manufacturing Organization and GMP radiopharmacy network, has signed a commercial supply agreement with Lantheus Holdings, Inc. (the parent company of Progenics Pharmaceuticals, Inc. (Progenics)) to manufacture and distribute Lantheus’ lead investigational prostate cancer imaging agent, PyL™ (18F-DCFPYL).